Divya Mehta results 12
· Newest (Page 1/1, per page 25)
Author: Divya Mehta ×Clear All Filters
Search Results
Ibrutinib (IBR) is a biopharmaceutical classification system (BCS) class II drug and an irreversible Bruton’s tyrosine kinase (BTK) inhibitor. IBR has an extremely low oral bioavailability due to the activity of the CYP3A4 enzyme. The current intention of the research was to enhance solubility followed by oral bioavailability of IBR using the hot melt extrusion (HME) technique by formulating drug-drug cocrystals (DDCs). Ketoco...
Previous1Next